2.22
2.30%
0.05
Dopo l'orario di chiusura:
2.15
-0.07
-3.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Precedente Chiudi:
$2.17
Aprire:
$2.18
Volume 24 ore:
1.21M
Relative Volume:
2.35
Capitalizzazione di mercato:
$159.46M
Reddito:
$31.25M
Utile/perdita netta:
$-88.48M
Rapporto P/E:
-1.4323
EPS:
-1.55
Flusso di cassa netto:
$-79.63M
1 W Prestazione:
+29.82%
1M Prestazione:
+86.55%
6M Prestazione:
+63.24%
1 anno Prestazione:
-58.66%
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Nome
Aclaris Therapeutics Inc
Settore
Industria
Telefono
484-324-7933
Indirizzo
701 LEE ROAD, WAYNE, PA
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2022-12-14 | Iniziato | Stifel | Buy |
2022-12-01 | Iniziato | Goldman | Buy |
2022-10-06 | Iniziato | BTIG Research | Buy |
2021-07-23 | Ripresa | Jefferies | Buy |
2021-06-15 | Iniziato | Piper Sandler | Overweight |
2021-04-21 | Iniziato | H.C. Wainwright | Buy |
2019-10-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2019-09-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
2019-06-27 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2019-05-06 | Iniziato | SVB Leerink | Outperform |
2018-03-28 | Ripresa | Leerink Partners | Outperform |
2018-02-09 | Iniziato | Guggenheim | Buy |
2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
2016-11-29 | Iniziato | Leerink Partners | Outperform |
2016-09-30 | Iniziato | JMP Securities | Mkt Outperform |
2016-06-10 | Iniziato | Guggenheim | Buy |
2015-11-02 | Iniziato | Citigroup | Buy |
2015-11-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 19.7% in October - MarketBeat
Aclaris Therapeutics (NASDAQ:ACRS) Shares Cross Above 50-Day Moving AverageWhat's Next? - MarketBeat
Contrasting Star Equity (NASDAQ:STRR) and Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc - Yahoo Finance
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Renaissance Technologies LLC - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $23.50 Consensus Target Price from Analysts - MarketBeat
Stonepine Capital Management LLC Purchases New Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Investing in Aclaris Therapeutics Inc (ACRS) Is Getting More Attractive - Knox Daily
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MSN
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
Accenture (NYSE:ACN) PT Raised to $365.00 - Defense World
Arcellx Sees Unusually Large Options Volume (NASDAQ:ACLX) - Defense World
Research Analysts’ Price Target Changes for September 18th (ACN, AGF.B, ANIP, ANP, APA, AZPN, BDC, BKR, BLDR, BNTX) - Defense World
Investing in Astrazeneca plc ADR (AZN) Is Getting More Attractive - Knox Daily
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
Metric Deep Dive: Understanding Accenture plc (ACN) Through its Ratios - The Dwinnex
American Century Companies Inc. Boosts Stock Position in Accel Entertainment, Inc. (NYSE:ACEL) - Defense World
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial - Clinical Trials Arena
Capricor Therapeutics (NASDAQ:CAPR) Receives “Buy” Rating from HC Wainwright - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Receives “Neutral” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Investing in Acrivon Therapeutics Inc (ACRV) Is Getting More Attractive - Knox Daily
Accel Entertainment CEO sells shares worth over $49,000 By Investing.com - Investing.com UK
Arch Capital Group (ACGL) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
AstraZeneca PLC ADR outperforms competitors despite losses on the day - MarketWatch
Capricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by HC Wainwright - MarketBeat
Meeder Advisory Services Inc. Makes New Investment in AstraZeneca PLC (NASDAQ:AZN) - Defense World
William Blair Investment Management LLC Sells 17,390 Shares of AstraZeneca PLC (NASDAQ:AZN) - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Receives "Neutral" Rating from HC Wainwright - MarketBeat
Arch Capital Group (NASDAQ:ACGL) Sets New 1-Year High at $114.69 - MarketBeat
(ACEL) Long Term Investment Analysis - Stock Traders Daily
Analyzing Axcelis Technologies Inc (ACLS) After Recent Trading Activity - Knox Daily
Quest Partners LLC Cuts Stake in Accel Entertainment, Inc. (NYSE:ACEL) - Defense World
Financial Metrics Exploration: Understanding Acrivon Therapeutics Inc (ACRV) Through Ratios - The Dwinnex
Market Watch: Aclarion Inc (ACON)’s Noteworthy Drop, Closing at 0.18 - The Dwinnex
Citi lifts Accenture stock price target on growth prospects - Investing.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Analysts - MarketBeat
Aclaris Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis - Yahoo Finance
Quest Partners LLC Grows Position in Cardlytics, Inc. (NASDAQ:CDLX) - Defense World
Arch Capital Group (ACGL) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Accenture (ACN) Rises Higher Than Market: Key Facts - Yahoo Finance
AstraZeneca PLC ADR rises Monday, outperforms market - MarketWatch
Market Momentum: Astrazeneca plc ADR (AZN) Registers a -0.87 Decrease, Closing at 78.27 - The Dwinnex
Acrivon Therapeutics: Promising Trial Results and FDA Clearance - TipRanks
Acrivon Therapeutics upgraded to Buy on cancer data at Ladenburg - TipRanks
ICA Group Wealth Management LLC Decreases Stock Position in Accenture plc (NYSE:ACN) - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Lifted to Strong-Buy at StockNews.com - Defense World
Aclaris Therapeutics Inc Azioni (ACRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aclaris Therapeutics Inc Azioni (ACRS) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
1.30 |
130,317 |
169,555 |
13,578,286 |
Leonard Braden Michael | 10% Owner |
Jul 22 '24 |
Buy |
1.33 |
17,716 |
23,557 |
13,602,691 |
Leonard Braden Michael | 10% Owner |
Jul 19 '24 |
Buy |
1.30 |
6,689 |
8,696 |
13,584,975 |
Leonard Braden Michael | 10% Owner |
Jul 03 '24 |
Buy |
1.16 |
143,288 |
166,071 |
13,324,952 |
Leonard Braden Michael | 10% Owner |
Jul 05 '24 |
Buy |
1.15 |
123,017 |
141,334 |
13,447,969 |
Leonard Braden Michael | 10% Owner |
Jul 02 '24 |
Buy |
1.14 |
86,092 |
98,489 |
13,181,664 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):